FDA approves Breckenridge’s Megace ES generic

FDA approves Breckenridge’s Megace ES generic

The Food and Drug Administration has approved Breckenridge Pharmaceuticals’ generic of Megace ES (megestrol acetate oral suspension).

Megestrol acetate.svg

The drug is a concentrated suspension that is indicated to treat loss of appetite, severe malnutrition or unexplained significant weight loss in patients with AIDS. The drug had generic and brand sales of $17.6 million for the 12 months ended October 2017, according to IQVIA data.

The Boca Raton, Fla.-based company said the product was launching immediately, having resolved litigation between it, Par Pharmaceuticals and Alkermes Pharma Ireland.


Share this:
December 6, 2017 / Pharma News